February 2017 : Trod Medical is mentioned in Medical Device Daily (PDF)

Leuven, Belgium, February 8, 2017. Trod Medical NV, the medical device company with FDA-cleared and CE Marked products for focal ablation, announces the issuance of a new patent allowance by the United States Patent and Trademark Office (USPTO), entitled "Method of percutaneous localized or focal treatment of prostate lesions using radio frequency", with patent ID US 20110288541 A1.

The patent covers a surgical technique for application with Trod Medical's Encage™ radio frequency ablation device used in Prostate Focal Therapy. The patent is part of a family of patents, including one for a "Method to remove a tumor using a percutaneous surgical instrument", with patent ID US 9445866 B2, announced in August 2016.

"This new patent adds an additional layer of protection, extending beyond families of patents we have covering Encage's original design, including robotic handling, and guiding systems", said Andre Faure, CEO of Trod Medical. He continued, "Our strong family of patents, combined with Encage's superior clinical outcomes for men with prostate cancer, puts Trod Medical in a dominant position in this very significant and growing market".

TROD Medical's Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation.


About TROD Medical NV

TROD Medical is a medical device company, focused on the development of tools for use in the focal ablation of soft tissues. The Company, founded in 2006 by Dr. Andre Faure, has developed significant expertise in developing innovative ablation technologies, particularly radio frequency (RF) ablation devices.

Trod Medical’s proprietary product, Encage™, is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.

TROD Medical is a private venture-backed company with headquarteres in Leuven (Belgium) and facilities in the Tampa Bay area, Florida (USA), and Paris (France).

For additional information, please contact:

TROD Medical andre.faure@trodmedical.com
Andre Faure, CEO
Instinctif Partners trod@instinctif.com
Daniel Gooch / Christelle Kerouedan +44 (0)20 7457 2020

Leuven, Belgium, August 1, 2016 - Trod Medical NV, the medical device company with FDA-cleared and CE Marked products for focal ablation, announces the issuance of a new patent allowance by the United States Patent and Trademark Office (USPTO), entitled "Method to remove a tumor using a percutaneous surgical instrument".

The patent covers a surgical technique used with Trod Medical's Encage™ radio frequency ablation device, including the technique of enlarging the margin of the tissue destruction area, particularly important in Prostate Focal Therapy

"This new patent adds an additional layer of protection, even beyond the other families of patents we have from Encage's original design and guiding systems", said Andre Faure, CEO of Trod Medical. He continued, "This, combined with Encage's superior clinical outcomes, will put Trod in a dominant position in this very significant and growing market".

TROD Medical's Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation.


Notes to Editors

About TROD Medical NV

TROD Medical is a medical device company, focused on the development of tools for use in the focal ablation of soft tissues. The Company, founded in 2006 by Dr. Andre Faure, has developed significant expertise in developing innovative ablation technologies, particularly radio frequency (RF) ablation devices.

Trod Medical's proprietary product, Encage, is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.

TROD Medical is a private venture-backed company with headquarters in Leuven (Belgium) and facilities in the Tampa Bay area (USA), and Paris (France).

For additional information, please contact:

TROD Medical andre.faure@trodmedical.com
Andre Faure, CEO
Instinctif Partners trod@instinctif.com
Daniel Gooch / Christelle Kerouedan +44 (0)20 7457 2020

Leuven, Belgium, June 16, 2016 - TROD Medical NV, the medical device company developing tools for focal ablation announces completion of enrollment in its clinical study at two world-renown cancer research institutions, University College London (UCL) and New York University (NYU).

The clinical teams at NYU and UCL presented last month at the 111th American Urological Association's Annual Meeting (San Diego, CA), on patients treated with Encage. Together with a study running at the Moffitt Cancer Center (Tampa, Florida), over 40 patients have now been treated using Encage. Results not yet published show total tissue destruction in target ablation zones and very significant reduction of side effect (erectile dysfunction and urinary incontinence rates down to 0%).

Prof. Mark Emberton from UCL said: "The wonderful thing about Encage is its simplicity. It uses an energy source that clinicians are familiar with and provides very controlled and predictable tissue destruction. It is also extremely versatile in that it can be used to treat small prostate cancers with precision but can also be used to treat the prostate in a zonal manner."

"Encage is a disruptive technology with the potential to maximize target ablation zones in the prostate while minimizing the all too common side effects associated with current treatments" said Andre Faure, CEO of TROD Medical. He continued, "This significant clinical work at prestigious US and UK institutions builds on the CE Mark Approval for Encage obtained in January 2016, and US FDA 510(k) clearance secured in 2008, and has led to significant attention from major strategic players in urology and surgical oncology."

TROD Medical's Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation.

Trod Medical will be attending the NYU Symposium on Advances in Prostate Imaging, Detection and Ablative Treatment of Prostate Cancer on 17-18 June in New York City.

Notes to Editors

About TROD Medical NV

TROD Medical is a medical device company, focused on the development of tools for use in the focal ablation of soft tissues. The Company, founded in 2006 by Dr. Andre Faure, has developed significant expertise in developing innovative ablation technologies, particularly radio frequency (RF) ablation devices.

Trod Medical's proprietary product, Encage, is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.

TROD Medical is a private venture-backed company with headquarters in Leuven (Belgium) and facilities in the Tampa Bay area (USA), and Paris (France).

For additional information, please contact:

TROD Medical andre.faure@trodmedical.com
Andre Faure, CEO
Instinctif Partners trod@instinctif.com
Daniel Gooch / Christelle Kerouedan / Lynne Trowbridge +44 (0)20 7457 2020

Leuven, Belgium, January 11, 2016. TROD Medical NV, the medical device company developing tools for focal ablation, today announced that it has received CE Mark Approval for its Encage™ device.

"Receiving CE Mark Approval for Encage™ is a major milestone for the Company" said Andre Faure, CEO of TROD Medical, "and builds on the US FDA 510(k) clearance secured in 2008."

TROD Medical’s Encage™ is a bipolar, radiofrequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. Encage™ is a breakthrough in treatment for prostate cancer, one of the most common soft tissue cancers in the world with around 240,000 new cases every year in the US alone. Encage™ has the potential to reduce the risk of side effects commonly associated with current treatments, including erectile dysfunction (impotence), and urinary and fecal incontinence.

About TROD Medical NV

TROD Medical is a medical device company, focused on the development of tools for use in the focal ablation of soft tissues. The Company, founded in 2006 by Dr. Andre Faure, has developed significant expertise in developing innovative ablation technologies, particularly radiofrequency (RF) ablation devices.

Trod Medical’s proprietary technology, Encage™, is a confined, bipolar, RF-based, helical ablation probe enabling minimally invasive focal ablation of soft tissues. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.

Clinical studies using the Encage™ device for treatment of prostate cancer are being performed at world renowned centers including: University College London (UCL) Hospitals, London; the J. Lee Moffitt Cancer Centre and Research Institute, Tampa, USA; the New York University (NYU) School of Medicine, NY, USA; and the Long Island Jewish (LIJ) School of Medicine, NY, USA.

TROD Medical is a VC-backed company with two co-leads, Capricorn Venture Partners and Vesalius Biocapital. The Company is headquartered in Leuven (Belgium) and has facilities in the Tampa Bay area, Florida (USA), and Paris (France).

March, 2015 : Trod Medical announces opening of a new clinical study at University College of London (UCL) Hospitals, with Prof. Mark Emberton and Prof. Hashim Ahmed (Focal Prostate Radiofrequency Ablation).
December, 2014 : Trod Medical announces opening of a new clinical study at H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA, with Prof. Julio Pow-Sang (Focal Prostate Radio-Frequency Ablation).
September, 2014: Trod Medical initiates clinical trials at New York University (NYU) School of Medecine, NY, USA, with Prof. Samir Taneja (MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer).
June, 2014: Trod Medical announces appointement of Don Deyo to Board of Directors.
January 2014 : Trod Medical signs an imaging software co-development with the University of Leuven (KUL LRD).
July 2013 : Trod Medical completes 4,75M€ series B financing co-led by Capricorn Ventures and Vesalius Biocapital (PDF)
2011 : Trod Medical initiates clinical study at the Long Island Jewish (LIJ) School of Medecine, NY, with Prof. Louis R. Kavoussi (Clinical evaluation of a novel bipolar radiofrequency ablation system for renal masses).

Events

17-18 June, 2016 : Trod Medical to present at the Symposium Advances in Prostate Imaging, Detection and Ablative Treatment of Prostate Cancer at the NYU Langone Medical Center, NY, USA.
6-10 May, 2016 : Trod Medical to present at the American Urology Association, San Diego, CA, USA.
21-23 June, 2015 : Trod Medical to present at the 8th International Symposium on Focal Therapy anf Imaging in prostate and kidney Cancer at Amsterdam, the Netherlands.
19-20 June, 2015 : Trod Medical to present at the Symposium Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer at the NYU Langone Medical Center, NY, USA.
15-19 May, 2015 : Trod Medical to present at the American Urology Association, New Orleans, LA, USA.
20-23 March, 2015 : Trod Medical to present at the European Association of Urology, Madrid, Spain.
21-23 August, 2014 : Trod Medical to present at the 7th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, Pasadena, Los Angeles, USA.
20-21 June, 2014 : Trod Medical to present at the Symposium Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer at the NYU Langone Medical Center, NY, USA.